Is pazopanib (Votrient) approved for the treatment of leiomyosarcoma?
A new therapeutic combination to combat resistant sarcomas has shown promise in a trial.
Meeting the challenges of the significant morbidity, functional impairment, and alterations in body image in patients undergoing this surgical resection.
A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.
A new analysis confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. In addition, hemoglobin at baseline was found to be a new prognostic factor.
A diagnosis of soft-tissue sarcoma can leave many patients unsure of what to do next. This fact sheet provides more information about this type of cancer and lists sources of support.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|